Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis

[1]  S. Ahn,et al.  Efficacy of adefovir add‐on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine‐resistant chronic hepatitis B , 2010, Journal of medical virology.

[2]  Matthew Kowgier,et al.  Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. , 2010, Gastroenterology.

[3]  S. Ziegler,et al.  Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case , 2010, Virology Journal.

[4]  L. Xue.  Comparision of the efficacy of two kinds of antiviral drugs Adefovir and Entecavir , 2010 .

[5]  L. Jiabin,et al.  Random study of Entecavir and Adefovir dipivoxil in patients with chronic hepatitis B. , 2010 .

[6]  Fang Yang,et al.  [Comparison of efficacy between adefovir dipivoxil and entecavir in patients with chronic hepatitis B]. , 2010, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[7]  G. Cao.  Clinical relevance and public health significance of hepatitis B virus genomic variations. , 2009, World journal of gastroenterology.

[8]  Xinyue Chen,et al.  [Efficacy and durability of generic adefovir dipivoxil in patients with HBeAg positive chronic hepatitis]. , 2009, Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology.

[9]  F. Zoulim,et al.  Hepatitis B virus resistance to nucleos(t)ide analogues. , 2009, Gastroenterology.

[10]  Rachel Wilson,et al.  Does RNA interference provide new hope for control of chronic hepatitis B infection? , 2009, Antiviral therapy.

[11]  J. Dienstag.  Benefits and risks of nucleoside analog therapy for hepatitis B , 2009, Hepatology.

[12]  A. Chou,et al.  HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapy. , 2009, Hepato-gastroenterology.

[13]  R. Fontana.  Side effects of long‐term oral antiviral therapy for hepatitis B , 2009, Hepatology.

[14]  J. Feld,et al.  Endpoints of therapy in chronic hepatitis B , 2009, Hepatology.

[15]  M. Ghany,et al.  Antiviral resistance and hepatitis B therapy , 2009, Hepatology.

[16]  A. Cross,et al.  Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir , 2009, Hepatology.

[17]  J. Dienstag.  Benefits and Risks of Nucleoside Analog Therapy for Hepatitis , 2009 .

[18]  C. Yeh,et al.  The Oncogenic Potential of Hepatitis B virus rtA181T/ Surface Truncation Mutant , 2008, Antiviral therapy.

[19]  G. Dusheiko,et al.  Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. , 2008, The Lancet. Infectious diseases.

[20]  F. T. P. Group,et al.  Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China , 2007, Hepatology International.

[21]  T. Asselah,et al.  Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. , 2005, Journal of hepatology.

[22]  L. Wang,et al.  Virology Journal , 1966, Nature.